XML 62 R51.htm IDEA: XBRL DOCUMENT v3.7.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
License agreements                        
Research and development expense             $ 201,839   $ 120,269 $ 609,811 $ 277,092  
Unrealized loss on long term investments             (19,574)   (854) (25,388) (3,804)  
Long term investment             144,425     $ 144,425   $ 31,987 [1]
Agenus                        
License agreements                        
Number of program targets | item       3   4            
Royalty payments on future global net sales (as a percent)                   15.00%    
Period of notice for termination of license agreement     12 months                  
Agenus | Development, Regulatory and Commercialization Milestones                        
License agreements                        
Additional milestone payments under the license agreement     $ 510,000                  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                        
License agreements                        
Royalty payments on future global net sales (as a percent)                   6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                        
License agreements                        
Royalty payments on future global net sales (as a percent)                   12.00%    
Agenus | Development Milestones                        
License agreements                        
Upfront payment under license agreement                   $ 20,000    
Agenus                        
License agreements                        
Research and development expense             11,200   4,000 18,900 8,100  
Shares owned following stock purchase (as a percent) 11.00%       9.00%              
Ownership percentage (as a percent) 18.00%                      
Unrealized loss on long term investments             (4,400)   $ (900) (3,300) $ (3,800)  
Long term investment             68,200     68,200   32,000
Total revenues               $ 27,000        
Net income (loss)               $ (17,100)        
Agenus | Accrued and other liabilities                        
License agreements                        
Accrued and other liabilities             $ 6,000     6,000   $ 11,400
Agenus | Stock purchase agreement                        
License agreements                        
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                    
Purchase price of common stock   $ 60,000                    
Per share price | $ / shares $ 4.40 $ 6.00                    
Discount for lack of marketability $ 4,500                      
Fair value of shares on the issuance date 39,500                      
Total consideration paid 60,000                      
Research and development expense                   $ 20,500    
Long term investment $ 39,500                      
[1] The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.